Back to Search Start Over

Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria: A Multicentric North American Experience.

Authors :
Ivanics, Tommy
Claasen, Marco P. A. W.
Samstein, Benjamin
Emond, Jean C.
Fox, Alyson N.
Pomfret, Elizabeth
Pomposelli, James
Tabrizian, Parissa
Florman, Sander S.
Mehta, Neil
Roberts, John P.
Emamaullee, Juliet A.
Genyk, Yuri
Hernandez-Alejandro, Roberto
Koji Tomiyama
Kazunari Sasaki
Koji Hashimoto
Shunji Nagai
Abouljoud, Marwan
Olthoff, Kim M.
Source :
Annals of Surgery; Jan2024, Vol. 279 Issue 1, p104-111, 8p
Publication Year :
2024

Abstract

Objective: To evaluate long-term oncologic outcomes of patients post--living donor liver transplantation (LDLT) within and outside standard transplantation selection criteria and the added value of the incorporation of the New York-California (NYCA) score. Background: LDLT offers an opportunity to decrease the liver transplantation waitlist, reduce waitlist mortality, and expand selection criteria for patients with hepatocellular carcinoma (HCC). Methods: Primary adult LDLT recipients between October 1999 and August 2019 were identified from a multicenter cohort of 12 North American centers. Posttransplantation and recurrence-free survival were evaluated using the Kaplan-Meier method. Results: Three hundred sixty LDLTs were identified. Patients within Milan criteria (MC) at transplantation had a 1, 5, and 10-year posttransplantation survival of 90.9%, 78.5%, and 64.1% versus outside MC 90.4%, 68.6%, and 57.7% (P = 0.20), respectively. For patients within the University of California San Francisco (UCSF) criteria, respective posttransplantation survival was 90.6%, 77.8%, and 65.0%, versus outside UCSF 92.1%, 63.8%, and 45.8% (P = 0.08). Fifty-three (83%) patients classified as outside MC at transplantation would have been classified as either low or acceptable risk with the NYCA score. These patients had a 5-year overall survival of 72.2%. Similarly, 28(80%) patients classified as outside UCSF at transplantation would have been classified as a low or acceptable risk with a 5-year overall survival of 65.3%. Conclusions: Long-term survival is excellent for patients with HCC undergoing LDLT within and outside selection criteria, exceeding the minimum recommended 5-year rate of 60% proposed by consensus guidelines. The NYCA categorization offers insight into identifying a substantial proportion of patients with HCC outside the MC and the UCSF criteria who still achieve similar post-LDLT outcomes as patients within the criteria. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00034932
Volume :
279
Issue :
1
Database :
Supplemental Index
Journal :
Annals of Surgery
Publication Type :
Academic Journal
Accession number :
175441304
Full Text :
https://doi.org/10.1097/SLA.0000000000006049